Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs Kumar Jeetendra | June 29, 2020 Mumbai, June 29, 2020 : Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”) and Boehringer Ingelheim India Pvt. Ltd. (BI) today announced their partnership in India to co-market three new oral anti-diabetics drugs Oboravo® (Empagliflozin), Oboravo Met® (Empagliflozin+Metformin) and Tiptengio® (Empagliflozin+Linagliptin) Empagliflozin is approved for glucose-control in patients with type-2 diabetes; …
